Market Overview

UPDATE: Aegis Capital Initiates Amarin Corporation with Buy, $25 PT; Risk-Mitigated Opportunity

Share:
Related AMRN
Benzinga's Top #PreMarket Losers
These 5 Stocks Have More Than Doubled In 2015
Amarin Corp. Quietly Gains Market Share, May Be Helped By Congress (Seeking Alpha)

Aegis Capital said on Monday that it initiated coverage on Amarin Corporation (NASDAQ: AMRN) with a Buy rating and a price target of $25.

Aegis Capital said, "In our view, Amarin constitutes one of the most risk-mitigated opportunities in the biotechnology sector, as the firm's lead product candidate has already successfully demonstrated safety and efficacy in two randomized, placebo-controlled Phase 3 clinical trials. These studies were conducted under Special Protocol Assessments (SPAs) from the U.S. FDA."

Amarin Corporation closed at $15.12 on Friday.

Latest Ratings for AMRN

DateFirmActionFromTo
Mar 2015HC WainwrightUpgradesBuy
Feb 2015SunTrust Robinson HumphreyUpgradesNeutralBuy
Nov 2014CitigroupMaintainsNeutral

View More Analyst Ratings for AMRN
View the Latest Analyst Ratings

Posted-In: Aegis CapitalAnalyst Color Price Target Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (AMRN)

Around the Web, We're Loving...

Get Benzinga's Newsletters